Cognition Therapeutics, Inc.CGTXNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +33.11% | +50.87% | +83.27% | +58.98% | +92.86% |
| Weighted Average Shares Diluted Growth | +33.11% | +50.87% | +83.27% | +58.98% | +92.86% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +105.68% | +109.68% | +454.94% | +102.81% | -43.60% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -28.87% | -14.02% | -39.51% | -42.91% | +57.35% |
| Book Value per Share Growth | -62.39% | -49.22% | -76.80% | -80.78% | +30.79% |
| Debt Growth | -21.30% | -34.25% | -38.59% | -42.15% | -34.48% |
| R&D Expense Growth | -2.37% | -29.71% | +2.21% | -0.83% | -66.88% |
| SG&A Expenses Growth | -0.16% | -28.42% | -14.38% | -19.48% | -15.27% |